Market Spotlight: Osteoarthritis and Osteoarthritis Pain
Market Spotlight: Osteoarthritis and Osteoarthritis Pain
$1,318.00
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 337.5 million prevalent cases of osteoarthritis (knee or hip) in adults aged 30 years and older worldwide, and forecasts that number to increase to 367.7 million prevalent cases by 2028.
- The global prevalence of osteoarthritis in adults aged 30 years and older is estimated to be 8.2%. The approved drugs in the osteoarthritis space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being topical, intraarticular, and transdermal formulations.
- The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II. Therapies in development for osteoarthritis focus on a wide variety of targets. The largest proportion of pipeline drugs are administered via the intraarticular route.
- High-impact upcoming events for drugs in the osteoarthritis space comprise topline Phase II trial results for MEDI7352, Zilosul, and EP-104IAR; topline Phase IIb trial results for MM-II and XT-150; and topline Phase III trial results for TLC599, lorecivivint, and Zilosul.
- The overall likelihood of approval of a Phase I osteoarthritis and osteoarthritis pain asset is 9.4%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 13.3 years from Phase I to approval, compared to 13.2 years in the overall rheumatology (non autoimmune) space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 57% of trials in Phase I–II, and 43% in Phase III–IV.
- The US has a substantial lead in the number of osteoarthritis clinical trials globally. Germany leads the major European markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the osteoarthritis space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for osteoarthritis, with 86 trials.
- Pfizer leads industry sponsors with the highest overall number of clinical trials for osteoarthritis.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Non-pharmacological treatment
9 Pharmacological treatment
10 Surgery
11 EPIDEMIOLOGY
14 MARKETED DRUGS
18 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 CNTX-4975 for Osteoarthritis and Osteoarthritis Pain (April 29, 2022)
28 Ampion for Osteoarthritis and Osteoarthritis Pain (April 20, 2022)
29 Ampion for Osteoarthritis and Osteoarthritis Pain (September 15, 2021)
29 AmnioFix for Osteoarthritis and Osteoarthritis Pain (September 13, 2021)
31 Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 25, 2021)
32 Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 22, 2021)
34 KEY UPCOMING EVENTS
35 KEY REGULATORY EVENTS
35 Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety
35 Tanezumab Receives Negative CHMP Opinion
35 US Fast-Track For OA Knee Therapy
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 Juniper Acquires Kolon’s Cell-Mediated Gene Therapy For Knee Osteoarthritis
37 CDRI Licenses Caviunin-Based Drug Compositions to Aveta Biomics
37 Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy
37 Biosplice Finds China Partner For Knee Osteoarthritis Drug In Haisco
38 Samil Gets South Korean Rights To Biosplice’s Knee Arthritis Compound
39 REVENUE OPPORTUNITY
40 CLINICAL TRIAL LANDSCAPE
41 Sponsors by status
42 Sponsors by phase
43 Recent events
44 BIBLIOGRAPHY
45 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2019–28
18 Figure 2: Overview of pipeline drugs for osteoarthritis in the US
18 Figure 3: Pipeline drugs for osteoarthritis, by company
19 Figure 4: Pipeline drugs for osteoarthritis, by drug type
19 Figure 5: Pipeline drugs for osteoarthritis, by classification
31 Figure 6: AmnioFix for Osteoarthritis and Osteoarthritis Pain (September 13, 2021): Phase IIb – dHACM (Knee Osteoarthritis)
34 Figure 7: Key upcoming events in osteoarthritis
36 Figure 8: Probability of success in the osteoarthritis and osteoarthritis pain pipeline
40 Figure 9: Clinical trials in osteoarthritis
40 Figure 10: Top 10 drugs for clinical trials in osteoarthritis
41 Figure 11: Top 10 companies for clinical trials in osteoarthritis
41 Figure 12: Trial locations in osteoarthritis
42 Figure 13: Osteoarthritis trials status
43 Figure 14: Osteoarthritis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of osteoarthritis (knee or hip), 2019–28
15 Table 2: Marketed drugs for osteoarthritis
20 Table 3: Pipeline drugs for osteoarthritis in the US
27 Table 4: CNTX-4975 for Osteoarthritis and Osteoarthritis Pain (April 29, 2022)
28 Table 5: Ampion for Osteoarthritis and Osteoarthritis Pain (April 20, 2022)
29 Table 6: Ampion for Osteoarthritis and Osteoarthritis Pain (September 15, 2021)
30 Table 7: AmnioFix for Osteoarthritis and Osteoarthritis Pain (September 13, 2021)
32 Table 8: Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 25, 2021)
33 Table 9: Tanezumab for Osteoarthritis and Osteoarthritis Pain (March 22, 2021)
39 Table 10: Historical global sales, by drug ($m), 2017–21
39 Table 11: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Ovarian Cancer 
Sign up to the